Granted Patent
B2
US 12,296,013 · App. 17/746,740 · Granted May 13, 2025
Photosensitizing antibody-fluorophore conjugates
A61K45/06A61K31/704A61K41/0071A61K47/6803A61K47/6869A61K49/0032A61K49/0058C07K16/2863C07K16/30C07K16/3069C07K16/32G01N33/5011A41D13/0002A41D2400/32A44C15/00A61K2039/505C07K2317/24C07K2317/73C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm −2 , thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
Claims (17)
1. A phototoxic pharmaceutical composition, comprising:
a phototoxic conjugate comprising an IR700 molecule conjugated to an antibody that binds to a cell surface protein on a cell, wherein the antibody is an anti-PSMA antibody that is J591 or an antigen binding fragment thereof; and
a pharmaceutically acceptable carrier.
2. The phototoxic pharmaceutical composition of claim 1 , wherein the antigen binding fragment is selected from a Fab fragment, a Fab′ fragment, a F(ab′) 2 fragment, a single chain Fv (scFv) or a disulfide stabilized Fv (dsFv).
3. The phototoxic pharmaceutical composition of claim 1 , wherein the cell is a tumor cell.
4. A combination, comprising:
a first pharmaceutical composition comprising a phototoxic conjugate comprising an IR700 molecule conjugated to an antibody that binds to a cell surface protein on a cell, wherein the antibody is an anti-PSMA antibody that is J591 or an antigen binding fragment thereof; and
a second pharmaceutical composition comprising an additional therapeutic agent.
5. The combination of claim 4 , wherein the first composition comprises a pharmaceutically acceptable carrier.
6. The combination of claim 4 , wherein the second composition comprises a pharmaceutically acceptable carrier.
7. The combination of claim 4 , wherein the first and second pharmaceutical composition are formulated separately.
8. The combination of claim 4 , wherein the additional therapeutic agent is an anti-cancer or anti-neoplastic agent.
9. The combination of claim 4 , wherein the additional therapeutic agent is a radiotherapeutic agent, a chemotherapeutic agent, an antibiotic, an alkylating agent, an antioxidant, or a kinase inhibitor.
10. The combination of claim 4 , wherein the additional therapeutic agent is selected from a microtubule binding agent, a DNA intercalator or cross-linker, a DNA synthesis inhibitor, a DNA or RNA transcription inhibitor, an antibody, an enzyme, an enzyme inhibitor and a compound that affects gene regulation.
11. The combination of claim 4 , wherein the additional therapeutic agent is paclitaxel, docetaxel, vinblastine, vindesine, vinorelbine, epothilone, colchicine, dolastatin 15, nocodazole, podophyllotoxin, rhizoxin, actinomycin D, daunorubicin, cisplatin, carboplatin, oxaliplatin, mitomycin C, bleomycin, chlorambucil, cyclophosphamide, methotrexate, 5-fluro-5′-deoxyuridine, 5-fluorouracil, camptothecin, etoposide, formestane, trichostatin, raloxifene, 5-azacytidine, 5-aza-2′-deoxycytidine, tamoxifen, 4-hydroxytamoxifen, mifepristone, imatinib, gefitinib, erlotinib, adriamycine, apigenin, rapamycine, zebularine, cimetidine, interleukin-2 (IL-2), or an anti-CTLA4 antibody.
12. The combination of claim 4 , wherein the antigen binding fragment is selected from a Fab fragment, a Fab′ fragment, a F(ab′) 2 fragment, a single chain Fv (scFv) or a disulfide stabilized Fv (dsFv).
13. The combination of claim 4 , wherein the cell is a tumor cell.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 17, 2022
From: KOBAYASHI, HISATAKA; CHOYKE, PETER
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 059936/0656 →
Continuity (5)
Provisional Application
61363079
· Jul 9, 2010
References Cited (314)
US 2915392A
· Pedersen
· 1959
[cited by applicant]
US 5196005A
· Doiron et al.
· 1993
[cited by applicant]
US 5494793A
· Schindele et al.
· 1996
[cited by applicant]
US 6344050B1
· Chen
· 2002
[cited by applicant]
US 6534041B1
· Licha et al.
· 2003
[cited by applicant]
US 7005518B2
· Peng et al.
· 2006
[cited by applicant]
US 7498029B2
· Hasan et al.
· 2009
[cited by applicant]
US 8524239B2
· Kobayashi
· 2013
[cited by examiner]
US 8623354B2
· Brown et al.
· 2014
[cited by applicant]
US 9358306B2
· Kobayashi
· 2016
[cited by examiner]
US 9538306B2
· Nakamura
· 2017
[cited by applicant]
US 20040120949A1
· Adolf et al.
· 2004
[cited by applicant]
US 20060188509A1
· Derynck et al.
· 2006
[cited by applicant]
US 20060231107A1
· Glickman et al.
· 2006
[cited by applicant]
US 20070020272A1
· Hasan
· 2007
[cited by applicant]
US 20080095699A1
· Zheng et al.
· 2008
[cited by applicant]
US 20080095950A1
· Hall-Goulle et al.
· 2008
[cited by applicant]
US 20080253960A1
· Zheng et al.
· 2008
[cited by applicant]
US 20100215575A1
· O'Neill et al.
· 2010
[cited by applicant]
US 20110082412A1
· Hyde et al.
· 2011
[cited by applicant]
US 20110288234A1
· Pandey et al.
· 2011
[cited by applicant]
US 20120070377A1
· Yahioglu et al.
· 2012
[cited by applicant]
US 20130039861A1
· Regino et al.
· 2013
[cited by applicant]
US 20130287688A1
· Jain et al.
· 2013
[cited by applicant]
US 20140309578A1
· Anvari
· 2014
[cited by applicant]
US 20150071923A1
· Wei et al.
· 2015
[cited by applicant]
US 20150343060A1
· Kovar et al.
· 2015
[cited by applicant]
US 20160256564A2
· Kobayashi et al.
· 2016
[cited by applicant]
US 20180149658A1
· Wu et al.
· 2018
[cited by applicant]
US 20190365897A1
· Garcia-Guzman et al.
· 2019
[cited by applicant]
US 20210079112A1
· Kobayashi et al.
· 2021
[cited by applicant]
US 20210401985A1
· Biel et al.
· 2021
[cited by applicant]
US 20220105184A1
· Biel et al.
· 2022
[cited by applicant]
CN 102585003
· 2012
[cited by applicant]
CN 103781495A
· 2014
[cited by applicant]
CN 104203286A
· 2014
[cited by applicant]
DE 19717904A1
· 1998
[cited by applicant]
EP 1512963A1
· 2005
[cited by applicant]
EP 2731626B1
· 2018
[cited by applicant]
JP 2003284757A
· 2003
[cited by applicant]
JP 2003344284A
· 2003
[cited by applicant]
JP 2006515892A
· 2006
[cited by applicant]
JP 2006517230A
· 2006
[cited by applicant]
JP 2007155722A
· 2007
[cited by applicant]
JP 2014523907A
· 2014
[cited by applicant]
WO WO2000062807A1
· 2000
[cited by applicant]
WO WO2001057495
· 2001
[cited by applicant]
WO WO2003011106A2
· 2003
[cited by applicant]
WO WO2003032900A2
· 2003
[cited by applicant]
WO WO2003083811A1
· 2003
[cited by applicant]
WO WO2004038378A2
· 2004
[cited by applicant]
WO WO2004067038A1
· 2004
[cited by applicant]
WO WO2004071571A1
· 2004
[cited by applicant]
WO WO2005099689
· 2005
[cited by applicant]
WO WO2006092598A2
· 2006
[cited by applicant]
WO WO2007070680A2
· 2007
[cited by applicant]
WO WO2007092772
· 2007
[cited by applicant]
WO WO2007147001
· 2007
[cited by applicant]
WO WO2008005942A2
· 2008
[cited by applicant]
WO WO2008120134A1
· 2008
[cited by applicant]
WO WO2008152424
· 2008
[cited by applicant]
WO WO2009038776
· 2009
[cited by applicant]
WO WO2009079024A1
· 2009
[cited by applicant]
WO WO2009092062
· 2009
[cited by applicant]
WO WO2009107139A1
· 2009
[cited by applicant]
WO WO2010047611A1
· 2010
[cited by applicant]
WO WO2010085651A1
· 2010
[cited by applicant]
WO WO2010121163
· 2010
[cited by applicant]
WO WO2011014726A1
· 2011
[cited by applicant]
WO WO2011025950
· 2011
[cited by applicant]
WO WO2011038006
· 2011
[cited by applicant]
WO WO2011039510
· 2011
[cited by applicant]
WO WO2011039511
· 2011
[cited by applicant]
WO WO2011097248
· 2011
[cited by applicant]
WO WO2011123742A1
· 2011
[cited by applicant]
WO WO2012076631
· 2012
[cited by applicant]
WO WO2012082118
· 2012
[cited by applicant]
WO WO2013009475A1
· 2013
[cited by applicant]
WO WO2013044156
· 2013
[cited by applicant]
WO WO2014084394A1
· 2014
[cited by applicant]
WO WO2014089247
· 2014
[cited by applicant]
WO WO2014127365
· 2014
[cited by applicant]
WO WO2014168950
· 2014
[cited by applicant]
WO WO2015057692
· 2015
[cited by applicant]
WO WO2015187651
· 2015
[cited by applicant]
WO WO2015187677
· 2015
[cited by applicant]
WO WO2016022896A1
· 2016
[cited by applicant]
WO WO2017027247A1
· 2017
[cited by applicant]
WO WO2017031363
· 2017
[cited by applicant]
WO WO2017031367A1
· 2017
[cited by applicant]
WO WO2017040384
· 2017
[cited by applicant]
WO WO2018080952
· 2018
[cited by applicant]
WO WO2018156815
· 2018
[cited by applicant]
WO WO2018175403A1
· 2018
[cited by applicant]
WO WO2019009941
· 2019
[cited by applicant]
WO WO2019199751A1
· 2019
[cited by applicant]
Sasikumar et al., BioDrugs, 32:481-497. (Year: 2018).
[cited by examiner]
Shepard et al., “Developments in therapy with monoclonal antibodies and related proteins,”
[cited by applicant]
Ko et al., “An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies,”
[cited by applicant]
Agostinis et al., “Photodynamic Therapy of Cancer: An Update,”
[cited by applicant]
Ali et al., “Dynamic fluorescent imaging with indocyanine green for monitoring the therapeutic effects of photoimmunotherapy,”
[cited by applicant]
Amoury et al., “Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand,”
[cited by applicant]
Anonymous, “Anodyne: Tratamento com tecnologia MIRE,” Forumenfermagem—Projecto Feridas, Jan. 24, 2011, XP002686605, retrieved from the internet: URL:http://forumenfermagem.org/feridas/?s=anodyne, retrieved on Nov. 7, 20…
[cited by applicant]
Anonymous, “Near Infrared Light for the Treatment of Painful Peripheral Neuropathy,” U.S. National Institutes of Health, Aug. 2, 2012, XP002686617, retrieved from the internet: URL:http://www.clinicaltrials.gov/ct2/show…
[cited by applicant]
Anonymous, “Near IR Signature Management for Combat Clothing and Equipment,” Australian Government Department of Defence, DSTO, Apr. 7, 2005, XP002686606, retrieved from the internet: URL:http://www.dsto.defence.gov.au/…
[cited by applicant]
Ballou et al., “Tumor Labeling in Vivo Using Cyanine-Conjugated Monoclonal Antibodies,”
[cited by applicant]
Baolin et al., Practical Pathophysiology, Qing Dao Ocean University Press, Dec. 1995. (see English translation of CN201280043973.2 Notification of Reexamination (pp. 5-6) for relevance).
[cited by applicant]
Barrett et al., “In vivo Diagnosis of Epidermal Growth Factor Receptor Expression using Molecular Imaging with a Cocktail of Optically Labeled Monoclonal Antibodies,”
[cited by applicant]
Bartl et al., “Emissivity of aluminum and its importance for radiometric measurement,” Measurement of Physical Quantities, 31-36, 2004.
[cited by applicant]
BIO Clinica, vol. 19, p. 398-403, 2004 (in Japanese, with concise description in English).
[cited by applicant]
Busch et al., “Increasing Damage to Tumor Blood Vessels during Motexafin Lutetium-PDT through Use of Low Fluence Rate,”
[cited by applicant]
Carcenac et al., “Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates.”
[cited by applicant]
Carter et al., “Identification and Validation of Cell Surface Antigens for Antibody Targeting in Oncology,”
[cited by applicant]
Chauhan et al., “Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels,”
[cited by applicant]
Chen et al., “Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications,”
[cited by applicant]
Chiarello, K., “In between the light and the dark: developments in Photosensitive Pharmaceuticals,”
[cited by applicant]
Chopra, “IRDye 700DX-Labeled annexin V,” Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Oct. 27, 2009 [updated Dec. 17, 20…
[cited by applicant]
Clinical Trial Identifier NCT02422979, first posted on Apr. 22, 2015. Last updated on Sep. 20, 2019.
[cited by applicant]
CN 201280043973.2 First Office Action dated Nov. 24, 2014, with English translation (19 pages).
[cited by applicant]
CN 201280043973.2 Office Action dated Feb. 22, 2016 for Application No. 201280043973.2 (with English translation).
[cited by applicant]
CN 201280043973.2 Reexamination Notification dated Nov. 17, 2016, with English translation.
[cited by applicant]
CN 201280043973.2 Second Office Action dated Aug. 12, 2015, with English translation (15 pages).
[cited by applicant]
Dancey et al., “Phase I Trial of the 131I-Labelled Anti-CD25 Antibody Basiliximab in the Treatment of Patients with Relapsed or Refractor Lymphoma,”
[cited by applicant]
Davis et al., “Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer,”
[cited by applicant]
De Boer et al., “A standardized light-emitting diode device for photoimmunotherapy,”
[cited by applicant]
De Boer et al., “Biodistribution Study of Intravenously Injected Cetuximab-IRDye700DX in Cynomolgus Macaques,”
[cited by applicant]
Del Governatore et al., “Experimental Photoimmunotherapy of Hepatic Metastases of Colorectal Cancer with a 17.1A chlorin
[cited by applicant]
Denis et al., “Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy,”
[cited by applicant]
Dixit et al., “Transferrin Receptor-Targeted Theranostic Gold Nanoparticles for Photosensitizer Delivery in Brain Tumors,”
[cited by applicant]
Doane et al., “Observation and Photophysical Characterization of Silicon Phthalocyanine J-Aggregate Dimers in Aqueous Solutions,”
[cited by applicant]
Dolmans et al., “Targeting Tumor Vasculature and Cancer Cells in Orthotopic Breast Tumor by Fractionated Photosensitizer Dosing Photodynamic Therapy,”
[cited by applicant]
Dougherty et al., “Photodynamic Therapy,”
[cited by applicant]
Duska et al., Combination Photoimmunotherapy and Cisplatin: Effects on Human Ovarian Cancer Ex Vivo,
[cited by applicant]
EP12738664.7 Examination Report dated Jul. 6, 2016.
[cited by applicant]
Gajewski et al., “The P815 Mastocytoma Tumor Model,”
[cited by applicant]
Gao et al., “In vivo Cancer Targeting and Imaging With Semiconductor Quantum Dots,”
[cited by applicant]
Gleysteen et al.,“Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment,”
[cited by applicant]
Greish, Khaled, “Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines,”
[cited by applicant]
Hanaoka et al., “Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy,”
[cited by applicant]
Hanaoka et al., “Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel,”
[cited by applicant]
Heukers et al., “Nanobody-photosensitizer conjugates for targeted photodynamic therapy,”
[cited by applicant]
Hiroshima et al., “Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model,”
[cited by applicant]
Houston et al., “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,”
[cited by applicant]
Iqbal et al., “Phthalocyanine-Biomolecule Conjugated Photosensilizers for Targeted Photodynamic Therapy and Imaging,”
[cited by applicant]
Ishida et al., “Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer,”
[cited by applicant]
Ishii et al., “Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma,”
[cited by applicant]
Ito et al., “Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular…
[cited by applicant]
Ito et al., “Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms,”
[cited by applicant]
Jia et al., “Cannabinoid CB2 receptor as a new phototherapy target for the inhibition of tumor growth,”
[cited by applicant]
Jing et al., “Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies,”
[cited by applicant]
JP 2014520202 Final Official Action dated Sep. 28, 2016, with English translation.
[cited by applicant]
JP 2014-520202 Office Action dated Feb. 3, 2016, with English translation.
[cited by applicant]
Kabolizadeh et al., “The role of cetuximab in the management of head and neck cancers,”
[cited by applicant]
Kijanka et al., “Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization,”
[cited by applicant]
Kines et al., “HPV Based Photodynamic Therapy: A New Approach for Anti-Cancer Therapy,”
[cited by applicant]
Kirveliene et al., “Schedule-Dependent Interaction Between Doxorubicin and mTHPC-Mediated Photodynamic Therapy in Murine Hepatoma In Vitro and In Vivo,” Cancer Chemother. Pharmacol. 57:65-72, 2005.
[cited by applicant]
Kishimoto et al., “Evaluation of oxygen dependence on in vitro and in vivo cytotoxicity of photoimmunotherapy using IR-700-antibody conjugates,”
[cited by applicant]
Kobayashi, “Near infrared photoimmunotherapy: A new cancer therapy kills cancer cells with exposure of harmless near infrared light,” Poster Presentation, at NEST Conference, Tokyo, Japan, Apr. 2018.
[cited by applicant]
Kobayashi, “Activatable Fluorescent Imaging Probes for Cancer Detection and Diagnosis,” Abstract presented at the American Chemical Society meeting in San Francisco, 2014.
[cited by applicant]
Kovar et al., “A Systematic Approach to the Development of Fluorescent Contrast Agents for Optical Imagining of Mouse Cancer Models,”
[cited by applicant]
Kuhn et al., “The Role of Interleukin-2 Receptor Alpha in Cancer,”
[cited by applicant]
Lee et al., “Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis,”
[cited by applicant]
Li et al., “Structural basis for inhibition of the epidermal growth factor receptor by cetuximab,”
[cited by applicant]
Li-Cor, “High Photostability of IRDye® 700DX,” Retrieved on Aug. 23, 2018. Retrieve on https://www.licor.com/bio/products/reagents/irdye/700dx/photostability.html.
[cited by applicant]
Li-Cor, “IRDye® Infrared Dyes: Advancing Discovery with Infrared Imaging,” 2010.
[cited by applicant]
Maawy et al., “Near infra-red photoimmunotherapy with anti-CEA-IR700 results in extensive tumor lysis and a significant decrease in tumor burden in orthotopic mouse models of pancreatic cancer,”
[cited by applicant]
Maawy et al., “Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models,”
[cited by applicant]
Marabelle et al., “Depleting tumor-specific Tregs at a single site eradicates disseminated tumors,”
[cited by applicant]
Maruoka et al., “Combined CD44- and CD25-targeted Near-Infrared Photoimmunotherapy to Selectively Kill Cancer and Regulatory T cells in Syngeneic Mouse Cancer Models,”
[cited by applicant]
Master et al., “A Cell-targeted Photodynamic Nanomedicine Strategy for Head & Neck Cancers,”
[cited by applicant]
Maya et al., “Synthesis, Aggregation Behavior and Nonlinear Absorption Properties of Lead Phthalocyanines Substituted with Siloxane Chains,”
[cited by applicant]
McHugh et al., “The role of suppressor T cells in regulation of immune responses,”
[cited by applicant]
Medical Sci Digest., 2004, vol. 30, p. 545-548 (In Japanese, with concise description in English).
[cited by applicant]
Mitchell et al., “Comparison of Two Infrared Devices in Their Effectiveness in Reducing Symptoms Associated with RLS,” Physiother. Theory Prac., 2011, XP002686651, retrieved from the internet: URL:http://www.ncbi.nlm.ni…
[cited by applicant]
Mitchell et al., “Comparison of Two Infrared Devices in Their Effectiveness in Reducing Symptoms Associated with RLS,”
[cited by applicant]
Mitsunaga et al., “Abstract 3618: Target-Specific Photo-Activatable Immunotherapy (PIT) for Cancer Based on a Monoclonal Antibody-Photosensitizer Conjugate,” in
[cited by applicant]
Mitsunaga et al., “Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy,”
[cited by applicant]
Mitsunaga et al., “Cancer Cell-Selective in Vivo Near Infrared Photomimmunotherapy Targeting Specific Membrane Molecules,”
[cited by applicant]
Mitsunaga et al., “Near-Infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate,”
[cited by applicant]
Moore et al., “Photoimmunotherapy of residual disease after incomplete surgical resection in head and neck cancer models,”
[cited by applicant]
Nagaya et al., “Host Immunity Following Near-Infrared Photoimmunotherapy is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors,”
[cited by applicant]
Nagaya et al., “Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT),”
[cited by applicant]
Nagaya et al., “Near infrared photoimmunotherapy of B-cell lymphoma,”
[cited by applicant]
Nagaya et al., “Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody,”
[cited by applicant]
Nagaya et al., “Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen,”
[cited by applicant]
Nagaya et al., “Near infrared photoimmunotherapy with an anti-mesothelin antibody,”
[cited by applicant]
Nagaya et al., “Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody,”
[cited by applicant]
Nagaya et al., “Syngeneic Mouse Models of Oral Cancer are Effectively Targeted by Anti-CD44-Based NIR-PIT,”
[cited by applicant]
Nakajima et al., “Improving the Efficacy of Photoimmunotherapy (PIT) Using a Cocktail of Antibody Conjugates in a Multiple Antigen Tumor Model,”
[cited by applicant]
Nakajima et al., “Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging,”
[cited by applicant]
Nakajima et al., “The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity,”
[cited by applicant]
Nakamura et al., “MR imaging biomarkers for evaluating therapeutic effects shortly after near infrared photoimmunotherapy,”
[cited by applicant]
New Pharmacology (New Yakurigaku), Nankodo Co., Ltd., 2012, the third impression of the revised sixth edition, p. 558-559 (4 pages). (In Japanese, with translation).
[cited by applicant]
Nowis et al., “The influence of photodynamic therapy on the immune response,”
[cited by applicant]
Ogawa et al., “In vivo Molecular Imaging of Cancer with a Quenching Near-Infrared Fluorescent Probe Using Conjugates of Monoclonal Antibodies and Indocyanine Green,”
[cited by applicant]
Onizuka et al., “Tumor Rejection by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor α) Monoclonal Antibody,”
[cited by applicant]
PCT/US2012/044421 International Search Report and Written Opinion dated Nov. 26, 2012 (18 pages). (Discloses/discusses relevance of “Anonymous,‘Anodyne: Tratamento . . . ’”.
[cited by applicant]
PCT/US2015/044168 International Search Report and Written Opinion mailed on Oct. 19, 2016 (11 pages).
[cited by applicant]
PCT/US2016/045090 International Search Report and Written Opinion mailed on Oct. 11, 2016 (12 pages).
[cited by applicant]
PCT/US2019/026488 International Search Report and Written Opinion mailed on Jun. 26, 2019 (15 pages).
[cited by applicant]
Peng et al., “A nonfluorescent, broad-range quencher dye for Förster resonance energy transfer assays,”
[cited by applicant]
Peng et al., “Phthalocyanine Dye as an Extremely Photostable and Highly Fluorescent Near-Infrared Labeling Reagent,”
[cited by applicant]
Rosas-Arellano et al., “A simple solution for antibody signal enhancement in immunofluorescence and triple immunogold assays,”
[cited by applicant]
Rosenthal et al., “In Vivo Detection of Head and Neck Cancer Orthotopic Xenografts by Immunofluorescence,”
[cited by applicant]
Sanchez-Barcelo et al., “Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy,”
[cited by applicant]
Sano et al., “Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET,”
[cited by applicant]
Sano et al., “The effect of photoimmunotherapy (PIT) followed by liposomal daunorubicin in a mixed tumor model: A demonstration of the super-enhanced permeability and retention (SUPR) effect after PIT,”
[cited by applicant]
Sano et al., “Markedly Enhanced Permeability and Retention Effects Induced by Photo-Immunotherapy of Tumors,” ACS Nano. 7:717-724, 2013, including 19 pages of supporting information).
[cited by applicant]
Sasikumar et al., “Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways,”
[cited by applicant]
Sato et al., “Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor,”
[cited by applicant]
Sato et al., “Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy,”
[cited by applicant]
Sato et al., “Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy,”
[cited by applicant]
Sato et al., “Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy,”
[cited by applicant]
Sato et al., “Near infrared photoimmunotherapy for lung metastases,”
[cited by applicant]
Sato et al., “Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer,”
[cited by applicant]
Sato et al., “Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: preclinical experience,”
[cited by applicant]
Sato et al., “Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model,”
[cited by applicant]
Sato et al., “Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine,”
[cited by applicant]
Savellano et al., “Multiepitope HER2 Targeting Enhances Photoimmunotherapy of HER2-Overexpressing Cancer Cells with Pyropheophorbide-a Immunoconjugates,”
[cited by applicant]
Scully et al., “Application of Fluorescence Lifetime Imaging Microscopy to the Investigation of Intracellular PDT Mechanisms,”
[cited by applicant]
Sekkat et al., “Like a bolt from the Blue: Phthalocyanines in Biomedical Optics,”
[cited by applicant]
Serebrovskaia et al., “Genetically Encoded Photoimmunosensitizer,”
[cited by applicant]
Serebrovskaya et al., “Targeting Cancer Cells by Using an Antireceptor Antibody-Photosensitizer Fusion Protein,”
[cited by applicant]
SG 2013091822 Search Report and Written Opinion dated Mar. 20, 2015 (9 pages).
[cited by applicant]
SG 2013091822 Written Opinion dated Nov. 11, 2015 (10 pages).
[cited by applicant]
Sharman et al., “Targeted Photodynamic Therapy Via Receptor-Mediated Delivery Sytems,”
[cited by applicant]
Shimoyama et al., “Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells,”
[cited by applicant]
Shirasu et al., “Potent and specific antitumor effect of CEA-targeted photoimmunotherapy,”
[cited by applicant]
Simpson et al., “Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma,”
[cited by applicant]
Snyder et al., “Photodynamic therapy: a means to enhanced drug delivery to tumors,”
[cited by applicant]
Soukos et al., “Epidermal Growth Factor Receptor-Targeted Immunophotodiagnosis and Photoimmunotherapy of Oral Precancer in Vivo,”
[cited by applicant]
Steele et al., “Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells,”
[cited by applicant]
Sugiyama et al., “Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans,”
[cited by applicant]
Supplementary materials from Mitsunaga et al., “Cancer Cell-Selective in Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules,”
[cited by applicant]
Supplementary materials from Sugiyama et al., “Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans,”
[cited by applicant]
Turner et al., “Administration of substances to laboratory animals: routes of administration and factors to consider,”
[cited by applicant]
Van Cutsem et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,”
[cited by applicant]
Van Cutsem et al., “Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study,”
[cited by applicant]
Van Dongen et al., “Photosensitizer-Antibody Conjugates for Detection and Therapy of Cancer,”
[cited by applicant]
Van Driel et al., “EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer,”
[cited by applicant]
Von Felbert et al., “A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR,”
[cited by applicant]
Vrouenraets et al., “Targeting of Aluminum (III) Phthalocyanine Tetrasulfonate by Use of Internalizing Monoclonal Antibodies: Improved Efficacy in Photodynamic Therapy,”
[cited by applicant]
Waite and Roth, “Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities,”
[cited by applicant]
Wang et al., “Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen,”
[cited by applicant]
Watanabe et al., “Photoimmunotherapy Targeting Prostate-Specific Membrane Antigen: Are Antibody Fragments as Effective as Antibodies?,”
[cited by applicant]
Wessels et al., “Advances in cellular, subcellular, and nanoscale imaging in vitro and in vivo,”
[cited by applicant]
Wollina, “Cetuximab in non-melanoma skin cancer,”
[cited by applicant]
Wooldridge et al.., “Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma,”
[cited by applicant]
Xu et al., “Antibody Conjugated Magnetic Iron Oxide Nanoparticles for Cancer Cell Separation in Fresh Whole Blood,”
[cited by applicant]
Yoon et al., “Advance in Photosensitizers and Light Delivery for Photodynamic Therapy,”
[cited by applicant]
Zhang et al., “Target-selective phototherapy using a ligand-based photosensitizer for type 2 cannabinoid receptor,”
[cited by applicant]
Zhang et al., “Tumor mitochondria-targeted photodynamic therapy with a translocator protein (TSPO)-specific photosensitizer,”
[cited by applicant]
Zhu et al., “Visualization of P53
[cited by applicant]
Zinn et al., “IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus Macaques.”
[cited by applicant]
Zuluaga et al., “Combination of Photodynamic Therapy With Anti-Cancer Agents,”
[cited by applicant]
Safi et al., “Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer,”
[cited by applicant]
Nakaya and Kurata, “Possibility of Immunotherapy in combination with cytotoxic chemotherapy/radiotherapy,”
[cited by applicant]
PCT/US2022/014448 International Search Report and Written Opinion mailed on May 13, 2022 (14 pages).
[cited by applicant]
U.S. Appl. No. 17/841,110, Not yet published, Kobayashi et al.
[cited by applicant]
Forde et al., “Enhancement of electroporation facilitated immunogene therapy via T-reg depletion,”
[cited by applicant]
Spring et al., “Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates,”
[cited by applicant]
Azoury, “Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety”, Current Cancer Drug Targets, (2015) 15:452-462.
[cited by applicant]
Chung et al. “Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose,” N Engl J Med., 2008, 358(11):1109-17.
[cited by applicant]
De Goejj et al. “Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63,” Mol. Cancer Ther., 2016, 15(11):2688-96.
[cited by applicant]
Forde et al., “Enhancement of electroporation facilitated immunogene therapy via T-reg depletion,” Cancer Gene Therapy (Jul. 18, 2014), 21:349-354.
[cited by applicant]
Kang et al. “Rapid Formulation Development for Monoclonal Antibodies,”
[cited by applicant]
Lowe et al., “Aggregation, stability, and formulation of human antibody therapeutics,” Adv Protein Chem Struct Biol (2011) 84:41-61.
[cited by applicant]
Mittendorf et al., “PD-L1 expression in triple-negative breast cancer,”
[cited by applicant]
Spring et al., “Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates,” Proceedings of the National Academy of Sciences, 2014, 111(10):E933-E…
[cited by applicant]
Warne, “Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development,” Eur J Pharm Biopharm (2011) 78(2):208-12.
[cited by applicant]
Whiteley et al. (Jul. 2021), “Leukaemia: a model metastatic disease,”
[cited by applicant]
Cited By (1)